Cargando…

(68)Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients

We evaluated the clinical utility of (68)Ga-PSMA-11 PET/CT for staging and risk stratification of treatment-naïve prostate cancer (PCa) and metastatic castrate-resistant prostate cancer (mCRPC). Twenty-two consecutive patients with treatment-naïve PCa and 18 with mCRPC were enrolled. (68)Ga-PSMA-11...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zang, Shiming, Shao, Guoqiang, Cui, Can, Li, Tian-Nv, Huang, Yue, Yao, Xiaochen, Fan, Qiu, Chen, Zejun, Du, Jin, Jia, Ruipeng, Sun, Hongbin, Hua, Zichun, Tang, Jun, Wang, Feng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355341/ https://www.ncbi.nlm.nih.gov/pubmed/28103574 http://dx.doi.org/10.18632/oncotarget.14691

Ejemplares similares

Preparation of (68)Ga-PSMA-11 with a Synthesis Module for Micro PET-CT Imaging of PSMA Expression during Prostate Cancer Progression
por: Wang, Yuebing, et al.
Publicado: (2018)

Development and validation of (68)Ga-PSMA-11 PET/CT-based radiomics model to detect primary prostate cancer
por: Zang, Shiming, et al.
Publicado: (2022)

(68)Ga-PSMA-11 PET/CT combining ADC value of MRI in the diagnosis of naive prostate cancer: Perspective of radiologist
por: Wang, Liwei, et al.
Publicado: (2020)

Prediction of Biochemical Recurrence After Radical Prostatectomy Based on Preoperative (68)Ga-PSMA-11 PET/CT
por: Qiu, Xuefeng, et al.
Publicado: (2021)

Musculoskeletal pitfalls in (68)Ga-PSMA PET/CT
por: Pontes, Írline Cordeiro de Macedo, et al.
Publicado: (2023)

Multiparametric dynamic whole-body PSMA PET/CT using [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007
por: Dias, André H., et al.
Publicado: (2023)

Primary Staging of Prostate Cancer Patients with [(18)F]PSMA-1007 PET/CT Compared with [(68)Ga]Ga-PSMA-11 PET/CT
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

(68)Ga-PSMA-11 PET/CT versus (68)Ga-PSMA-11 PET/MRI for the detection of biochemically recurrent prostate cancer: a systematic review and meta-analysis
por: Huang, Ruizhe, et al.
Publicado: (2023)

Voxel-based comparison of [(68)Ga]Ga-RM2-PET/CT and [(68)Ga]Ga-PSMA-11-PET/CT with histopathology for diagnosis of primary prostate cancer
por: Fassbender, Thomas Franz, et al.
Publicado: (2020)

A prospective head-to-head comparison of [(68)Ga]Ga-P16-093 and [(68)Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer
por: Wang, Guochang, et al.
Publicado: (2023)

Detection efficacy of [(89)Zr]Zr-PSMA-617 PET/CT in [(68)Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer
por: Rosar, Florian, et al.
Publicado: (2023)

Cost-effectiveness of the implementation of [(68)Ga]Ga-PSMA-11 PET/CT at initial prostate cancer staging
por: van der Sar, Esmée C. A., et al.
Publicado: (2022)

PSMA-Positive Follicular Thyroid Carcinoma Incidentally Detected by [(68)Ga]Ga-PSMA-11 PET/CT: Correlation with Immunohistology Confirms Neovascular PSMA-Expression
por: Rosar, Florian, et al.
Publicado: (2022)

Comparison of (68)Ga-PSMA-11 PET/CT with (11)C-acetate PET/CT in re-staging of prostate cancer relapse
por: Regula, Naresh, et al.
Publicado: (2020)

PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and (68)Ga‐PSMA‐11 PET Using Cyclotron‐Produced (68)Ga
por: Thompson, Scott M., et al.
Publicado: (2021)

The influence of digital PET/CT on diagnostic certainty and interrater reliability in [(68)Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer
por: Alberts, Ian, et al.
Publicado: (2021)

Comparison of [(18)F]PSMA-1007 with [(68)Ga]Ga-PSMA-11 PET/CT in Restaging of Prostate Cancer Patients with PSA Relapse
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

Hybrid imaging with [(68)Ga]PSMA-11 PET-CT and PET-MRI in biochemically recurrent prostate cancer
por: Glemser, P. A., et al.
Publicado: (2022)

Investigation of the halo-artifact in (68)Ga-PSMA-11-PET/MRI
por: Heußer, Thorsten, et al.
Publicado: (2017)

[(68)Ga]Ga-PSMA-11: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
por: Hennrich, Ute, et al.
Publicado: (2021)

Staging Prostate Cancer with (68)Ga-PSMA-11 PET/CT in the Elderly: Is Preimaging Biopsy Imperative?
por: Kesler, Mikhail, et al.
Publicado: (2023)

Impact of [(177)Lu]Lu-PSMA-617 Radioligand Therapy on Reference Organ Uptake Assessed by [(68)Ga]Ga-PSMA-11-PET/CT
por: Groener, Daniel, et al.
Publicado: (2023)

Comparison of (68)Ga-PSMA-11 PET-CT with mpMRI for preoperative lymph node staging in patients with intermediate to high-risk prostate cancer
por: Zhang, Qing, et al.
Publicado: (2017)

Integration of CT urography improves diagnostic confidence of (68)Ga-PSMA-11 PET/CT in prostate cancer patients
por: Will, Leon, et al.
Publicado: (2017)

(68)Ga-PSMA PET-CT Imaging of Metastatic Adenoid Cystic Carcinoma
por: de Keizer, Bart, et al.
Publicado: (2016)

Specificity of (68)Ga-PSMA PET/CT for Prostate Cancer - Myths and Reality
por: Sasikumar, Arun
Publicado: (2017)

Letter to the Editor: (68)Ga-PSMA-11 for renal cortical PET imaging
por: Sarikaya, Ismet
Publicado: (2022)

Dual-Time Point [(68)Ga]Ga-PSMA-11 PET/CT Hybrid Imaging for Staging and Restaging of Prostate Cancer
por: Hoffmann, Manuela A., et al.
Publicado: (2020)

Interobserver agreement of [(68)Ga]Ga-PSMA-11 PET/CT images interpretation in men with newly diagnosed prostate cancer
por: Derwael, Céline, et al.
Publicado: (2020)

(68)Ga PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer
por: Iravani, Amir, et al.
Publicado: (2017)

Baseline [(68)Ga]Ga-PSMA-11 PET/CT before [(177)Lu]Lu-PSMA-617 Radioligand Therapy: Value of PSMA-Uptake Thresholds in Predicting Targetable Lesions
por: Groener, Daniel, et al.
Publicado: (2023)

The meta-analysis of the effect of (68)Ga-PSMA-PET/CT diagnosis of prostatic cancer compared with bone scan
por: Zhao, Ruining, et al.
Publicado: (2021)

(68)Ga-PSMA PET/CT Versus (18)F-FDG PET/CT for Imaging of Hepatocellular Carcinoma
por: Gündoğan, Cihan, et al.
Publicado: (2021)

Analysis of Pros and Cons in Using [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007: Production, Costs, and PET/CT Applications in Patients with Prostate Cancer
por: Maisto, Costantina, et al.
Publicado: (2022)

Prostate Cancer Biochemical Recurrence Resulted Negative on [(68)Ga]Ga-PSMA-11 but Positive on [(18)F]Fluoromethylcholine PET/CT
por: Laudicella, Riccardo, et al.
Publicado: (2022)

Diagnostic value of two-time point [(68)Ga]Ga-PSMA-11 PET/CT in the primary staging of untreated prostate cancer
por: Weitzer, Friedrich, et al.
Publicado: (2023)

(68)Ga-PSMA-PET/CT for the evaluation of liver metastases in patients with prostate cancer
por: Damjanovic, Jonathan, et al.
Publicado: (2019)

Re: The role of (68)Ga-PSMA-PET/CT in radiotherapy planning in prostate cancer
por: Cihan, Yasemin Benderli
Publicado: (2019)

Active Giant Cell Vasculitis Diagnosis with (68)Ga PSMA PET/CT Imaging
por: Sağer, Muhammet Sait, et al.
Publicado: (2021)

Performance of Ga-68 PSMA PET/CT for diagnosis and grading of local prostate cancer
por: Kwan, Timothy N., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_j5aq7l0ernuf2nf5oi77kfkdsc